Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...

Litifilimab was superior to placebo for reducing skin disease activity in cutaneous lupus erythematosus, according to phase 2 ...

With recent attention on noninvasive, dermatologic cosmetic procedures—such as laser resurfacing of scars and collagen fillers—more people, including those with lupus, are inquiring about the ...

With enpatoran soon entering Phase III clinical trials, the Phase II safety and efficacy results support the drug’s development.

A first-in-class monoclonal antibody has shown significant reductions in skin disease in patients with cutaneous lupus erythematosus (CLE). Litifilimab met the primary endpoint of reduction of disease ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Please provide your email address to receive an email when new articles are posted on . Patients with systemic lupus with a history of skin rashes are likely to have high interferon levels. This ...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving ...

Lucille, a 57 years old high school physical education coach, started experiencing a rash on her cheeks and nose. The rash worsened every time she went outside. She had been suffering from joint pain ...

Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the natural active ingredient ...